Agios Pharmaceuticals (AGIO) Insider Scott Biller Sells 3,000 Shares

Agios Pharmaceuticals (NASDAQ:AGIO) insider Scott Biller sold 3,000 shares of the business’s stock in a transaction dated Thursday, April 5th. The shares were sold at an average price of $75.20, for a total transaction of $225,600.00. Following the completion of the sale, the insider now directly owns 60,196 shares of the company’s stock, valued at approximately $4,526,739.20. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Scott Biller also recently made the following trade(s):

How to Become a New Pot Stock Millionaire
  • On Monday, March 5th, Scott Biller sold 3,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $83.08, for a total transaction of $249,240.00.
  • On Monday, February 5th, Scott Biller sold 3,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $76.04, for a total transaction of $228,120.00.
  • On Wednesday, January 10th, Scott Biller sold 3,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $65.00, for a total transaction of $195,000.00.

Shares of Agios Pharmaceuticals stock traded up $6.78 on Monday, reaching $80.00. 710,523 shares of the stock were exchanged, compared to its average volume of 601,720. The company has a market cap of $4,197.46, a PE ratio of -11.85 and a beta of 1.98. Agios Pharmaceuticals has a one year low of $45.11 and a one year high of $87.00.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported ($1.81) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.65) by ($0.16). The company had revenue of $9.80 million during the quarter, compared to the consensus estimate of $12.65 million. Agios Pharmaceuticals had a negative net margin of 731.60% and a negative return on equity of 76.67%. Agios Pharmaceuticals’s revenue for the quarter was down 56.7% on a year-over-year basis. During the same period in the previous year, the company earned ($1.34) EPS. equities analysts predict that Agios Pharmaceuticals will post -6.25 earnings per share for the current year.

AGIO has been the subject of a number of recent analyst reports. Oppenheimer reaffirmed a “buy” rating and set a $83.00 price target on shares of Agios Pharmaceuticals in a report on Monday, December 11th. Canaccord Genuity set a $90.00 price target on shares of Agios Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, December 12th. BidaskClub downgraded shares of Agios Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, December 16th. Royal Bank of Canada upped their price target on shares of Agios Pharmaceuticals to $91.00 and gave the stock an “outperform” rating in a report on Thursday, January 18th. They noted that the move was a valuation call. Finally, Zacks Investment Research raised shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating and set a $84.00 price target for the company in a report on Tuesday, January 16th. Three research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. Agios Pharmaceuticals presently has an average rating of “Buy” and an average price target of $85.50.

A number of large investors have recently modified their holdings of the stock. Capital International Investors lifted its stake in Agios Pharmaceuticals by 0.3% in the 3rd quarter. Capital International Investors now owns 3,138,131 shares of the biopharmaceutical company’s stock valued at $209,470,000 after purchasing an additional 8,294 shares during the last quarter. First Trust Advisors LP lifted its stake in Agios Pharmaceuticals by 26.3% in the 4th quarter. First Trust Advisors LP now owns 813,647 shares of the biopharmaceutical company’s stock valued at $46,516,000 after purchasing an additional 169,331 shares during the last quarter. Alkeon Capital Management LLC lifted its stake in Agios Pharmaceuticals by 12.0% in the 4th quarter. Alkeon Capital Management LLC now owns 511,619 shares of the biopharmaceutical company’s stock valued at $29,250,000 after purchasing an additional 54,858 shares during the last quarter. Geode Capital Management LLC lifted its stake in Agios Pharmaceuticals by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 369,512 shares of the biopharmaceutical company’s stock valued at $21,125,000 after purchasing an additional 4,073 shares during the last quarter. Finally, UBS Asset Management Americas Inc. lifted its stake in Agios Pharmaceuticals by 965.5% in the 4th quarter. UBS Asset Management Americas Inc. now owns 345,284 shares of the biopharmaceutical company’s stock valued at $19,740,000 after purchasing an additional 312,878 shares during the last quarter. 82.41% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This article was first published by Ticker Report and is owned by of Ticker Report. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://www.tickerreport.com/banking-finance/3344144/agios-pharmaceuticals-agio-insider-scott-biller-sells-3000-shares.html.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.

Insider Buying and Selling by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Investors Buy Shares of 3M  on Weakness
Investors Buy Shares of 3M on Weakness
Investors Buy Shares of Caterpillar  on Weakness
Investors Buy Shares of Caterpillar on Weakness
Inseego  Downgraded by ValuEngine
Inseego Downgraded by ValuEngine
ValuEngine Lowers Habit Restaurants  to Strong Sell
ValuEngine Lowers Habit Restaurants to Strong Sell
Community Trust Bancorp  Upgraded to Buy at ValuEngine
Community Trust Bancorp Upgraded to Buy at ValuEngine
QUALCOMM  Earns Hold Rating from Stifel Nicolaus
QUALCOMM Earns Hold Rating from Stifel Nicolaus


Leave a Reply

© 2006-2018 Ticker Report. Google+.